#China #Chengdu #ADC #Kelun-Biotech #SKB103

Kelun-Biotech's Major Breakthrough with IND Approval for SKB103

In a notable advance within the biopharmaceutical sector, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received Investigational New Drug (IND) approval from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) for their promising novel therapeutic, SKB103. This bispecific antibody-drug conjugate (bsADC) is designed to target Tumor-Associated Antigens (TAA) and inhibit PD-L1, making it a dual-action candidate for treating advanced solid tumors.

As Kelun-Biotech's inaugural TAA-PD-L1 bsADC, SKB103 builds upon the company's existing capabilities after the commercial success of their previously approved TROP2 and HER2 ADCs, which have demonstrated considerable clinical efficacy. This new treatment signifies Kelun-Biotech's ongoing commitment to push the boundaries of oncology therapeutics.

SKB103 utilizes the company's proprietary OptiDC™ platform, honing in on efficient delivery mechanisms for cytotoxic agents directly to tumor sites, all while modifying the tumor microenvironment. Results from preclinical trials have been promising, showing significant anti-tumor activity coupled with a commendable safety profile. This bodes well for its transition into clinical trials, where its true potential can be further clarified.

Dr. Michael Ge, CEO of Kelun-Biotech, articulated the importance of this milestone, stating, "The IND approval for SKB103 emphasizes our ongoing innovation in bispecific antibodies, reflecting our commitment to enhance our ADC pipeline. With our robust R&D capabilities and extensive ADC development experience, we are poised to lead the charge in the next generation of cancer therapies."

Kelun-Biotech, under the stock code 6990.HK, is not limited to SKB103. The company employs a comprehensive strategy focusing on various disease areas, majorly solid tumors, autoimmune, and metabolic disorders, with over 30 key innovative projects currently in the pipeline. The firm aims to address unmet health needs and strives to position itself as a frontrunner in the global biopharmaceutical landscape.

The approval of SKB103 not only represents a significant achievement for Kelun-Biotech but also marks a forward step in the evolving realm of cancer therapies. As global healthcare systems seek novel solutions to combat cancer, the advancements made with SKB103 could facilitate a brighter outlook for countless patients facing advanced stages of the disease. As development progresses, the industry watches with keen anticipation for the clinical insights that SKB103 will yield, ultimately paving the way for broader applications and transformative impacts in cancer treatment.

Overall, Kelun-Biotech's innovative approach leverages both technology and therapeutic insights in a bid to reshape the treatment landscape for cancer. By harnessing their proprietary platforms and extensive research capabilities, the company not only aims to elevate its positioning in the market but also to bring hope to patients and healthcare providers globally.

With the success of SKB103 and ongoing projects in the pipeline, Kelun-Biotech is indeed poised for a transformative journey in pioneering innovative therapies for patients battling some of the most challenging health conditions worldwide.